RxDoctor Payments Data

Heather Smith, PA

Medical · Seattle, WANPI 1487600540

Payments from drug & device makers

$2,252in general payments, 2019–2025

Across 28 payments — averaging $80.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$961
  • Astellas Pharma US Inc$380
  • Incyte Corporation$222
  • Stemline Therapeutics Inc.$153
  • Rigel Pharmaceuticals, Inc.$134
  • Otsuka America Pharmaceutical, Inc.$121
  • plus $282 from 7 others

What the payments were for

  • Consulting fees$56325%
  • Food & beverage$1,21054%
  • Education$47921%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,252 in reported general payments places this provider in the 80th percentile of 457 medical providers in Washington.

See all medical providers in Washington

Medicare billing

Part B allowed, 2024
$11,349
Medicare patients
43
Services billed
151

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate18$315,234
BosulifBosutinib27$253,051
SprycelDasatinib17$147,277
Imatinib Mesylate61$87,411
EliquisApixaban23$18,314
Atovaquone16$4,360
ValacyclovirValacyclovir Hcl45$2,822
Ursodiol25$2,254
Acyclovir80$1,519
Dapsone17$1,232
Sucralfate11$1,171
Gabapentin32$648
Hydroxyurea22$499
Potassium Chloride29$488
Clotrimazole12$373

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$222$315,23418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 457 medical providers in Washington.

Other medical in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →